BioSpace News Archive

The Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the FDA’s accelerated approval pathway. The bill, however, fails to adequately consider the whole picture.

Kite Pharma, a subsidiary of Gilead, announced that its Yescarta® has been approved by the U.S. Food and Drug Administration (FDA).

Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here’s more about it.

New data from Roche’s study on the use of Ocrevus to treat patients with primary and secondary progressive multiple sclerosis demonstrated positive outcomes.

Mavacamten is often referred to as “first-in-class” because it addresses the root cause of obstructions. Here’s everything you should know about its recent progress.

Before searching for a job in the life sciences industry, it is essential to understand the differences between working as a contractor and a full-time employee.

Merck strengthened its HPV vaccines manufacturing capacity with the expansion of its facility in Elkton, Virginia. Also, an additional 150 new jobs are created.

Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP. Fluidigm has been renamed Standard BioTools Inc. and its common stock is expected to begin trading on Nasdaq under the symbol “LAB” as of the open of market on April 6, 2022.

Myomo, Inc. provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue.

Applied Genetic Technologies Corporation today announced multiple presentations related to the Company’s ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and chromatopsia (ACHM) at the Association for Research in Vision and Ophthalmology’s 2022 Annual Meeting (ARVO 2022), taking place May 1 – 4, 2022 in Denver, Colorado.